GSA CAPITAL PARTNERS LLP

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1362033 LONDON, X0

Position in NTLA

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$2,285,818

+$190,429 QoQ

Shares Held

178,301

-23.5% QoQ

Ownership

0.128%

of shares outstanding

% of Portfolio

0.16%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $99,952,720 across 160 Biotechnology names. NTLA ranks #3 (2.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc. This page	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,285,818	178,301	-23.5%	Shares	Sole	2026-05-08
2025-12-31	$2,095,389	233,080	+210.4%	Shares	Sole	2026-02-06
2025-09-30	$1,296,821	75,091	-59.3%	Shares	Sole	2025-11-07
2025-06-30	$1,729,512	184,383	-16.2%	Shares	Sole	2025-07-22
2025-03-31	$1,563,616	219,918	+154.7%	Shares	Sole	2025-05-08
2024-12-31	$1,006,736	86,341	+22.7%	Shares	Sole	2025-02-07
2024-06-30	$1,574,544	70,355	+390.1%	Shares	Sole	2024-08-15
2022-12-31	$500,845	14,355	+37.9%	Shares	Sole	2023-02-13
2022-09-30	$582,375	10,407	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.